Omeros | OMER - Current Liabilities


Omeros reported $85.5M in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
Adma Biologics USD 75.76M 2.22M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Cytokinetics USD 181.43M 17.76M Jun/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Immunic USD 38.36M 7.74M Mar/2026
Insmed USD 438.74M 77.74M Jun/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
MacroGenics USD 108.82M 12.88M Jun/2026
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 122.01M 13.22M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Rockwell Medical USD 10.95M 259K Jun/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
United Therapeutics USD 607.8M 8.7M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026